LU92166I2 - Glycopyrronium ou un de ses sels - Google Patents

Glycopyrronium ou un de ses sels

Info

Publication number
LU92166I2
LU92166I2 LU92166C LU92166C LU92166I2 LU 92166 I2 LU92166 I2 LU 92166I2 LU 92166 C LU92166 C LU 92166C LU 92166 C LU92166 C LU 92166C LU 92166 I2 LU92166 I2 LU 92166I2
Authority
LU
Luxembourg
Prior art keywords
glycopyrrolate
dry powder
glycopyrronium
salt
formulation
Prior art date
Application number
LU92166C
Other languages
English (en)
French (fr)
Original Assignee
Sosei R & D Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9889490&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU92166(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sosei R & D Ltd filed Critical Sosei R & D Ltd
Publication of LU92166I2 publication Critical patent/LU92166I2/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Otolaryngology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Detergent Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Steroid Compounds (AREA)
LU92166C 2000-04-07 2013-03-13 Glycopyrronium ou un de ses sels LU92166I2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0008660.3A GB0008660D0 (en) 2000-04-07 2000-04-07 The treatment of respiratory diseases
PCT/GB2001/001606 WO2001076575A2 (en) 2000-04-07 2001-04-09 The treatment of respiratory diseases

Publications (1)

Publication Number Publication Date
LU92166I2 true LU92166I2 (fr) 2014-03-13

Family

ID=9889490

Family Applications (2)

Application Number Title Priority Date Filing Date
LU92166C LU92166I2 (fr) 2000-04-07 2013-03-13 Glycopyrronium ou un de ses sels
LU92393C LU92393I2 (fr) 2000-04-07 2014-03-07 Glycopyrronium ou un sel de celui-ci, plus particulièrement le sel bromure, combiné à indacatérol ouun sel de celui-ci, plus particulièrement le sel maléate

Family Applications After (1)

Application Number Title Priority Date Filing Date
LU92393C LU92393I2 (fr) 2000-04-07 2014-03-07 Glycopyrronium ou un sel de celui-ci, plus particulièrement le sel bromure, combiné à indacatérol ouun sel de celui-ci, plus particulièrement le sel maléate

Country Status (25)

Country Link
US (3) US7229607B2 (enExample)
EP (3) EP1449528B1 (enExample)
JP (1) JP5042426B2 (enExample)
CN (3) CN1292745C (enExample)
AT (1) ATE330585T2 (enExample)
AU (2) AU2004242450B2 (enExample)
BE (1) BE2013C023I2 (enExample)
BR (1) BR0109875A (enExample)
CA (1) CA2405705C (enExample)
CY (1) CY1105120T1 (enExample)
DE (1) DE60120936T3 (enExample)
DK (1) DK1267866T4 (enExample)
ES (2) ES2266242T5 (enExample)
GB (1) GB0008660D0 (enExample)
HK (1) HK1050846B (enExample)
HU (2) HU230958B1 (enExample)
IL (2) IL151791A0 (enExample)
LU (2) LU92166I2 (enExample)
MX (1) MXPA02009718A (enExample)
NO (3) NO336142B1 (enExample)
NZ (2) NZ535284A (enExample)
PL (1) PL364024A1 (enExample)
PT (1) PT1267866E (enExample)
WO (1) WO2001076575A2 (enExample)
ZA (1) ZA200207420B (enExample)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0008660D0 (en) * 2000-04-07 2000-05-31 Arakis Ltd The treatment of respiratory diseases
US8580306B2 (en) 2000-11-30 2013-11-12 Vectura Limited Particles for use in a pharmaceutical composition
EP2283817B1 (en) 2000-11-30 2016-05-18 Vectura Limited Method of making particles for use in a pharmaceutical composition
US20050130990A1 (en) * 2001-03-23 2005-06-16 Universite Laval Nicotinic receptor agonists for the treatment of inflammatory diseases
CA2341952A1 (en) 2001-03-23 2002-09-23 Universite Laval Nicotinic receptor agonists for the treatment of inflammatory pulmonary diseases
WO2002094321A1 (en) 2001-05-23 2002-11-28 Tanabe Seiyaku Co., Ltd. Compositions for promoting healing of bone fracture
KR20040007583A (ko) 2001-05-23 2004-01-24 다나베 세이야꾸 가부시키가이샤 연골 질환의 재생치료용 조성물
ME00077B (me) * 2002-03-01 2010-06-10 Chiesi Farm Spa Formoterol najfiniji preparat
US8039459B2 (en) 2004-07-15 2011-10-18 Universite Laval Nicotinic receptor agonists for the treatment of inflammatory diseases
US8557804B2 (en) 2002-03-25 2013-10-15 Universite Laval Nicotinic receptor agonists for the treatment of inflammatory diseases
US20040121003A1 (en) * 2002-12-19 2004-06-24 Acusphere, Inc. Methods for making pharmaceutical formulations comprising deagglomerated microparticles
AU2004263900A1 (en) * 2003-08-08 2005-02-17 Arriva Pharmaceuticals, Inc. Methods of protein production in yeast
GB0327723D0 (en) * 2003-09-15 2003-12-31 Vectura Ltd Pharmaceutical compositions
PT1684719E (pt) * 2003-11-14 2012-02-03 Baxter Int Composições de alfa-1-antitripsina e métodos de tratamento utilizando estas composições
ES2413011T3 (es) 2004-02-06 2013-07-15 Meda Pharma Gmbh & Co. Kg Combinación de anticolinérgicos y glucocorticoides para el tratamiento a largo plazo de asma y EPOC
AU2005210086A1 (en) * 2004-02-06 2005-08-18 Meda Pharma Gmbh & Co. Kg Treatment of rhinitis with anticholinergics alone in combination with antihistamines phosphodiesterase 4 inhibitors, or corticosteroids
CA2550848C (en) * 2004-02-06 2013-02-26 Meda Pharma Gmbh & Co. Kg Combination of anticholinergics and inhibitors of phosphodiesterase type 4 for the treatment of respiratory diseases
CA2550841C (en) * 2004-02-06 2012-10-02 Meda Pharma Gmbh & Co. Kg Novel combination of anticholinergic and .beta. mimetics for the treatment of respiratory diseases
JP2007524698A (ja) * 2004-02-27 2007-08-30 アルタナ　ファルマ　アクチエンゲゼルシャフト シクレソニドとグリコピロニウムとの組合せ物
US7914771B2 (en) * 2004-03-09 2011-03-29 Arriva Pharmaceuticals, Inc. Treatment of chronic obstructive pulmonary disease by low dose inhalation of protease inhibitor
GB0409703D0 (en) 2004-04-30 2004-06-02 Vectura Ltd Pharmaceutical compositions
GB0410398D0 (en) * 2004-05-10 2004-06-16 Arakis Ltd The treatment of respiratory disease
GB0410399D0 (en) * 2004-05-10 2004-06-16 Arakis Ltd The treatment of respiratory disease
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
EP1763344A1 (en) * 2004-06-29 2007-03-21 Boehringer Ingelheim International GmbH Medicaments for inhalation comprising steroids and an anticholinergic
EP1616567A1 (en) * 2004-07-16 2006-01-18 Boehringer Ingelheim Pharma GmbH & Co.KG Medicaments for inhalation comprising PDE IV inhibitors and glycopyrrolate salts
EP1789018A1 (en) 2004-08-27 2007-05-30 The Dow Chemical Company Enhanced delivery of drug compositions to treat life threatening infections
US20070105768A1 (en) * 2004-11-10 2007-05-10 Rajiv Nayar Dry recombinant human alpha 1-antitrypsin formulation
GB0425758D0 (en) 2004-11-23 2004-12-22 Vectura Ltd Preparation of pharmaceutical compositions
WO2006087919A1 (ja) * 2005-01-28 2006-08-24 Takeda Pharmaceutical Company Limited 難水溶性物質含有微細化組成物
SI1863476T1 (sl) 2005-03-16 2016-05-31 Meda Pharma Gmbh & Co. Kg Kombinacija antiholinergikov in antagonistov receptorja levkotriena za zdravljenje respiratornih bolezni
WO2006100453A1 (en) * 2005-03-24 2006-09-28 Sosei R & D Ltd. Glycopyrronium salts and their therapeutic use
WO2007070843A2 (en) * 2005-12-15 2007-06-21 Acusphere, Inc. Processes for making particle-based pharmaceutical formulations for oral administration
PL1971369T3 (pl) * 2005-12-21 2010-01-29 Meda Pharma Gmbh & Co Kg Połączenie R,R-glikopirolanu, rolipramu i budesonidu dla potrzeb leczenia chorób zapalnych
GB2434098A (en) * 2005-12-23 2007-07-18 Novartis Ag Process for the preparation of an inhalable dry powder formulation
WO2007109142A2 (en) * 2006-03-17 2007-09-27 Oregon Health & Science University M3 muscarinic receptor antagonists for treating tumors
GB0613161D0 (en) * 2006-06-30 2006-08-09 Novartis Ag Organic Compounds
US20100247658A1 (en) * 2007-12-13 2010-09-30 Gerhard Muhrer Organic compounds
WO2009074666A1 (en) * 2007-12-13 2009-06-18 Novartis Ag Organic compounds
US20090215734A1 (en) * 2008-02-26 2009-08-27 Elevation Pharmaceuticals, Inc. Method and system for the treatment of chronic obstructive pulmonary disease with nebulized anticholinergic administrations
US20100055045A1 (en) * 2008-02-26 2010-03-04 William Gerhart Method and system for the treatment of chronic obstructive pulmonary disease with nebulized anticholinergic administrations
ES2739352T3 (es) 2009-02-26 2020-01-30 Glaxo Group Ltd Formulaciones farmacéuticas que comprenden 4-{(1R)-2-[(6-{2-[(2,6-diclorobencil)oxi]etoxi}hexil)amino]-1-hidroxietil}-2-(hidroximetil)fenol
PT2435025T (pt) * 2009-05-29 2016-11-11 Pearl Therapeutics Inc Administração, por via respiratória, de agentes activos
US8815258B2 (en) 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
GB0921075D0 (en) 2009-12-01 2010-01-13 Glaxo Group Ltd Novel combination of the therapeutic agents
WO2011076841A2 (en) 2009-12-23 2011-06-30 Chiesi Farmaceutici S.P.A. Combination therapy for copd
RU2567040C2 (ru) 2009-12-23 2015-10-27 КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. Аэрозольная препаративная форма для лечения по поводу хронического обструктивного легочного заболевания
SG181870A1 (en) 2009-12-23 2012-07-30 Chiesi Farma Spa Aerosol formulation for copd
HRP20140582T4 (hr) 2009-12-23 2023-06-09 Chiesi Farmaceutici S.P.A. Kombinacijska terapija za copd
EP4008326A1 (en) 2010-09-29 2022-06-08 Pulmatrix Operating Company, Inc. Monovalent metal cation dry powders for inhalation
JOP20120023B1 (ar) * 2011-02-04 2022-03-14 Novartis Ag صياغات مساحيق جافة من جسيمات تحتوي على واحد أو اثنين من المواد الفعالة لعلاج امراض ممرات الهواء الانسدادية او الالتهابية
RS58456B1 (sr) 2011-08-01 2019-04-30 Univ Monash Postupak i formulacije za inhalaciju
US20150136130A1 (en) 2012-02-29 2015-05-21 Pulmatrix, Inc. Inhalable dry powders
JP6454323B2 (ja) 2013-03-15 2019-01-16 パール セラピューティクス，インコーポレイテッド 粒子状結晶性材料のコンディショニングのための方法及びシステム
KR20150135328A (ko) 2013-04-01 2015-12-02 풀매트릭스 인코퍼레이티드 티오트로피움 건조 분말
US9393202B2 (en) * 2013-04-26 2016-07-19 Chiesi Farmaceutici S.P.A Particle size reduction of an antimuscarinic compound
WO2015094927A1 (en) * 2013-12-17 2015-06-25 Merck Sharp & Dohme Corp. Media milling process for the manufacture of active pharmaceutical ingredients in propellants
AU2014375301C1 (en) 2013-12-30 2026-02-19 Chiesi Farmaceutici S.P.A. Stable pressurised aerosol solution composition of glycopyrronium bromide and formoterol combination
HRP20260435T1 (hr) 2014-09-09 2026-05-08 Vectura Limited Formulacija koja sadrži glikopirolat, postupak i uređaj
LT3193835T (lt) * 2014-09-15 2018-06-11 Verona Pharma Plc Skysta inhaliuojama vaisto forma, apimanti rpl554
MA41378A (fr) * 2015-01-20 2017-11-28 Teva Branded Pharmaceutical Prod R & D Inc Inhalateur de poudre sèche comprenant du propionate de fluticasone et du xinafoate de salmétérol
US20160310410A1 (en) 2015-04-24 2016-10-27 Glenmark Specialty S.A. Pharmaceutical compositions comprising arformoterol and glycopyrronium
MA43047A (fr) * 2015-06-15 2018-08-08 Qaam Pharmaceuticals Llc Sels d'acides gras de glycopyrronium et leurs procédés de production
US9925168B2 (en) * 2016-01-22 2018-03-27 Chiesi Farmaceutici S.P.A. Preparation of micronized particles of an antimuscarinic compound by hydrodynamic cavitation
US10098837B2 (en) 2016-07-28 2018-10-16 Chiesi Farmaceutici S.P.A. Combination therapy for COPD
PH12022551243A1 (en) 2019-12-02 2023-09-11 Chiesi Farm Spa Stainles steel can for pressurised metered dose inhalers

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3400197A (en) 1965-01-26 1968-09-03 Robins Co Inc A H Compressible sustained release pharmaceutical tablet lipid-colloidal silica gel matrix fragment granules
US5376386A (en) * 1990-01-24 1994-12-27 British Technology Group Limited Aerosol carriers
US5849263A (en) * 1993-03-30 1998-12-15 Charlotte-Mecklenburg Hospital Authority Pharmaceutical compositions containing alkylaryl polyether alcohol polymer
TW402506B (en) * 1993-06-24 2000-08-21 Astra Ab Therapeutic preparation for inhalation
DE4425255A1 (de) * 1994-07-16 1996-01-18 Asta Medica Ag Formulierung zur inhalativen Applikation
SA95160463B1 (ar) * 1994-12-22 2005-10-04 استرا أكتيبولاج مساحيق للاستنشاق
US5612053A (en) * 1995-04-07 1997-03-18 Edward Mendell Co., Inc. Controlled release insufflation carrier for medicaments
US5690374A (en) * 1996-04-19 1997-11-25 Nor-Easter Enterprises, Inc. Shock-absorbing tool handle
US6613795B2 (en) * 1996-11-11 2003-09-02 Christian Noe Enantiomerically pure basic arylcycloalkylhydroxycarboxylic esters, processes for their preparation and their use in medicaments
SI0937041T1 (en) * 1996-11-11 2003-10-31 Christian R. Noe Use of a pharmaceutically acceptable salt of (3R,2'R)-3-((Cyclopently-hydroxyphenylacetyl)oxy)-1,1-dimethyl-pyrrolidinium for the preparation of a medicament
DE69732306T2 (de) * 1997-01-16 2006-01-12 Massachusetts Institute Of Technology, Cambridge Zubereitung von partikelhaltigen arzneimitteln zur inhalation
SE9700133D0 (sv) * 1997-01-20 1997-01-20 Astra Ab New formulation
US6461591B1 (en) * 1997-02-05 2002-10-08 Jago Research Ag Medical aerosol formulations
US6495167B2 (en) * 1997-03-20 2002-12-17 Schering Corporation Preparation of powder agglomerates
NZ509328A (en) * 1998-07-24 2002-11-26 Jago Res A Medicinal aerosol formulations
ATE234604T1 (de) * 1998-08-04 2003-04-15 Jago Res Ag Medizinische aerosolformulierungen
CN1150895C (zh) * 1998-11-13 2004-05-26 杰格研究股份公司 用于吸入给药的干粉
US6406745B1 (en) * 1999-06-07 2002-06-18 Nanosphere, Inc. Methods for coating particles and particles produced thereby
WO2001008681A1 (en) * 1999-08-02 2001-02-08 First Horizon Pharmaceutical Corporation Methods of administration of glycopyrrolate compositions
GB0008660D0 (en) 2000-04-07 2000-05-31 Arakis Ltd The treatment of respiratory diseases
US6758795B2 (en) * 2000-08-22 2004-07-06 Stephen Barber Adjustable water-fillable exercise weights
GB0029903D0 (en) * 2000-12-07 2001-01-24 Arakis Ltd Use of anti-muscarinic agents
GB0410398D0 (en) * 2004-05-10 2004-06-16 Arakis Ltd The treatment of respiratory disease
GB0410399D0 (en) * 2004-05-10 2004-06-16 Arakis Ltd The treatment of respiratory disease
TWI509631B (zh) 2011-02-25 2015-11-21 漢高智慧財產控股公司 用於電子裝置之可燒結銀薄片黏著劑

Also Published As

Publication number Publication date
MXPA02009718A (es) 2003-05-27
US8029768B2 (en) 2011-10-04
DK1267866T3 (da) 2006-10-23
WO2001076575A2 (en) 2001-10-18
AU2010200660B2 (en) 2012-04-19
PL364024A1 (en) 2004-11-29
US20050019271A1 (en) 2005-01-27
HUP0301518A2 (hu) 2003-08-28
IL151791A (en) 2015-05-31
ES2687751T3 (es) 2018-10-29
HUS1900056I1 (hu) 2020-02-28
AU2004242450A1 (en) 2005-01-20
JP5042426B2 (ja) 2012-10-03
US20030068280A1 (en) 2003-04-10
EP2193791A1 (en) 2010-06-09
DK1267866T4 (en) 2016-10-03
EP1267866B2 (en) 2016-07-20
DE60120936D1 (de) 2006-08-03
ES2266242T5 (es) 2016-10-04
HK1050846A1 (en) 2003-07-11
CN1422154A (zh) 2003-06-04
CA2405705C (en) 2011-06-07
US7368104B2 (en) 2008-05-06
NO20024708L (no) 2002-10-24
IL151791A0 (en) 2003-04-10
CA2405705A1 (en) 2001-10-18
BE2013C023I2 (enExample) 2020-06-24
DE60120936T2 (de) 2006-11-02
EP1449528A1 (en) 2004-08-25
BR0109875A (pt) 2004-07-20
NO336142B1 (no) 2015-05-26
GB0008660D0 (en) 2000-05-31
AU8930601A (en) 2001-10-23
ATE330585T2 (de) 2006-07-15
AU776913B2 (en) 2004-09-23
CY1105120T1 (el) 2010-03-03
WO2001076575A3 (en) 2002-03-28
LU92393I2 (fr) 2015-11-02
NZ535284A (en) 2006-04-28
PT1267866E (pt) 2006-10-31
CN101181263A (zh) 2008-05-21
DE60120936T3 (de) 2016-11-17
EP1267866B1 (en) 2006-06-21
EP1267866A2 (en) 2003-01-02
NO2015024I2 (no) 2015-11-25
NZ521476A (en) 2004-10-29
CN1720995A (zh) 2006-01-18
NO2015025I1 (no) 2015-12-07
HK1050846B (en) 2007-01-26
JP2003530344A (ja) 2003-10-14
AU2004242450B2 (en) 2010-06-03
US7229607B2 (en) 2007-06-12
US20080220073A1 (en) 2008-09-11
HU230958B1 (hu) 2019-06-28
EP1449528B1 (en) 2018-08-08
NO2015024I1 (no) 2015-11-25
CN101181263B (zh) 2011-07-06
NO20024708D0 (no) 2002-10-01
CN1292745C (zh) 2007-01-03
ZA200207420B (en) 2003-09-16
ES2266242T3 (es) 2007-03-01
AU2010200660A1 (en) 2010-03-11

Similar Documents

Publication Publication Date Title
NO2015024I2 (no) glykopyrronium eller et salt derav
WO2002015662A3 (en) Quinuclidine-substituted heteroaryl moieties for treatment of disease (nicotinic acetylcholine receptor antagonists
WO2002017358A3 (en) Quinuclidine-substituted heteroaryl moieties for treatment of disease (nicotinic acetylcholine receptor antagonists)
IL187438A0 (en) Pyrrolopyridine derivatives and pharmaceutical compositions containing the same
CY2020003I2 (el) Anti-il-12 αντισωματα, συνθεσεις, μεθοδοι και χρησεις για την θεραπευτικη αγωγη της παθολογιας του crohn
BR0212042A (pt) Composto, composição farmacêutica, método de tratamento ou prevenção de doenças, e, uso de um composto
BR0210122A (pt) Composto ou um sal farmaceuticamente aceitável do mesmo, método para o tratamento ou prevenção de uma doença, uso do composto ou de seu sal, e, método para preparar o mesmo
WO2003093250A3 (en) Positive allosteric modulators of the nicotinic acetylcholine receptor
WO2005032471A3 (en) Benzylether and benzylamino beta-secretase inhibitors for the treatment of alzheimer's disease
NO2014009I2 (no) Forbindelser, farmasøytiske sammensetninger og anvendelser derav, samt fremgangsmåte for å fremstille nevnte forbindelser
CL2007000789A1 (es) Compuestos derivados de malonamida, inhibidores de la gamma-secretasa; proceso de preparacion; composicion farmaceutica; y su uso en el tratamiento de la enfermedad de alzheimer.
WO2002042462A3 (en) Therapeutic agents and methods of use thereof for treating an amyloidogenic disease
MXPA05008172A (es) Derivados de malonamida como inhibidores gamma-secretasa.
YU92501A (sh) Levodop/karbidop/entakapon farmaceutski preparat
MXPA02011311A (es) Composicion novedosa.
BR0316350A (pt) Diaminotriazóis úteis como inibidores de proteìna cinases
WO2005051914A8 (en) Benzylether and benzylamino beta-secretase inhibitors for the treatment of alzheimer's disease
IL188942A0 (en) Benzimidazole derivatives and pharmaceutical compositions containing the same
MXPA04008152A (es) Compuestos azabiciclicos para el tratamiento de enfermedades.
BR0316458A (pt) Composto, composição farmacêutica, método de tratamento ou prevenção de doenças, método para intensificar a cognição em um paciente saudável, e, uso de um composto
CL2004000806A1 (es) Compuestos derivados de quinazolinas, inhibidores de quinasa p38, composicion farmaceutica, procedimiento de preparacion, utiles para tratar artritis, enfermedad de crohn, alzheimer, asma, ataque al corazon, sepsis, infarto al miocardio y otras.
NO20060149L (no) Farmasoytiske forbindelser av atorvastatin
PT1223972E (pt) Suspensao de uma proteina de epi-hne processo para a sua preparacao aerossol de po anidro derivado dela composicoes farmaceuticas contendo a referida suspensao ou aerossol e as suas utilizacoes
WO2006057945A3 (en) 2,3,4,6-substituted pyridyl derivative compounds useful as beta-secretase inhibitors for the treatment of alzheimer's disease
WO2008036316A3 (en) Piperidine and pyrrolidine beta-secretase inhibitors for the treatment of alzheimer's disease